A snapshot of Protocol 3 from the 6th edition of Protocols for High-Risk Pregnancies: An Evidence-Based Approach
Author: Kimberly Yonkers, Departments of Psychiatry; Obstetrics, Gynecology and Reproductive Sciences; and Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut
Synopsis: In this protocol, Dr Yonkers reviews the pathophysiology, diagnosis, management, and follow up of depression. Included is perspective on the role of pharmacotherapy and choice of drug, with consideration of teratogenic risks.
At some time in their lives, 1 in 5 women will suffer from depression and the risk is greatest during a woman’s reproductive years. Maternal depression As Dr Yonkers notes, the risk of birth defects associated with antidepressants is small but ob/gyns need to balance the potential for these adverse effects with the benefits of preventing a major depressive episode in a pregnant woman. Some research suggests that maternal depression may be associated with particular perinatal complications.
Key Messages:
• The pathophysiology of depression is unknown but biology may determine a woman’s underlying risk of having the condition.
• A diagnosis of depression requires that a patient have at least 5 of 9 symptoms described in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. The symptoms in DSM-5 range from depressed mood and diminished interest to decreased concentration and recurrent thoughts of suicide.
• Management of depression during pregnancy varies, depending on whether a woman’s illness is unipolar or bipolar. Regardless, consultation with a psychotherapist may be appropriate.
• Treatment with a mood stabilizer and an antidepressant is recommended for bipolar disorder. During pregnancy, first- and second-generation antipsychotics are associated with a lower risk of birth defects than anticonvulsants and lithium, and they have good mood stabilizing properties.
• Antidepressants can be prescribed for women with unipolar depression that does not respond adequately to psychotherapy or bipolar depression that does not respond to mood stabilizers.
• Selective serotonin reuptake inhibitors and bupropion are the antidepressants of choice for women of reproductive age because of their safety profile. Paroxetine should not be prescribed during the first trimester because it is associated with fetal cardiac malformations.
• Patients to whom pharmacotherapy is prescribed should be monitored for adverse effects and psychiatric status. A second visit 2 weeks later is recommended, and visits at 1-month intervals thereafter. It may take 6 to 8 weeks before a patient fully responds to treatment.
READ the complete protocol on depression from Protocols for High-Risk Pregnancies: An Evidence-Based Approach, 6th Edition, edited by John T Queenan, Catherine Y Spong, and Charles J Lockwood, now at:
www.contemporaryobgyn.net/protocols/depression
BUY the book
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More